All In Biotech

NDA 205122 · Upsher Smith Labs

Qudexy Xr

Topiramate · Oral

Last checked: Nov 20, 2026Latest source record: Mar 6, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2014

Mar 11, 2014

Approved uses

4

Original approval plus efficacy supplements

Registered trials

302

82 Phase 3, 10 recruiting

FAERS reports

50,790

38,762 serious, 5,657 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Sep 3, 2026.

QUDEXY XR is indicated for: Epilepsy: initial monotherapy for the treatment of partial-onset or primary generalized tonic-clonic seizures in patients 2 years of age and older ( 1.1 ); adjunctive therapy for the treatment of partial-onset seizures, primary generalized tonic-clonic seizures, or seizures associated with Lennox-Gastaut Syndrome in patients 2 years of age and older ( 1.2 ) Preventive treatment of migraine in patients 12 years of age and older ( 1.3 ) 1.1 Monotherapy Epilepsy QUDEXY XR is indicated as initial monotherapy for the treatment of partial-onset or primary generalized tonic-clonic seizures in patients 2 years of age and older. 1.2 Adjunctive Therapy Epilepsy QUDEXY XR is indicated as adjunctive therapy for the treatment of partial-onset seizures, primary generalized tonic-clonic seizures, and seizures associated with Lennox-Gastaut Syndrome in patients 2 years of age and older. 1.3 Migraine QUDEXY XR is indicated for the preventive treatment of migraine in patients 12 years of age and older.

Mechanism: The precise mechanisms by which topiramate exerts its anticonvulsant and preventive migraine effects are unknown; however, preclinical studies have revealed four properties that may contribute to topiramate's efficacy for epilepsy and the preventive treatment of migraine. Electrophysiological and biochemical evidence suggests that topiramate, at pharmacologically relevant concentrations, blocks voltage-dependent sodium channels, augments the activity of the neurotransmitter gamma-aminobutyrate at some subtypes of the GABA-A receptor, antagonizes the AMPA/kainate subtype of the glutamate...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

5 products under this application
  • QUDEXY XR · TOPIRAMATE 100MG · CAPSULE, EXTENDED RELEASE, ORAL · Prescription · TE AB2
  • QUDEXY XR · TOPIRAMATE 25MG · CAPSULE, EXTENDED RELEASE, ORAL · Prescription · TE AB2
  • QUDEXY XR · TOPIRAMATE 150MG · CAPSULE, EXTENDED RELEASE, ORAL · Prescription · TE AB2
  • QUDEXY XR · TOPIRAMATE 50MG · CAPSULE, EXTENDED RELEASE, ORAL · Prescription · TE AB2
  • QUDEXY XR · TOPIRAMATE 200MG · CAPSULE, EXTENDED RELEASE, ORAL · Prescription · TE AB2

Clinical trials

Interventional ClinicalTrials.gov studies with "Topiramate" as an intervention, any sponsor and status, largest first.

All 302 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective7,062
  • off label use5,701
  • headache3,701
  • nausea3,349
  • fatigue3,211
  • product use in unapproved indication2,627
  • pain2,577
  • migraine2,555
  • dizziness2,442
  • seizure2,293
  • diarrhoea2,219
  • condition aggravated2,216

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004139
2005254
2006207
2007196
2008383
2009775
2010941
20111,213
20121,395
20131,214
20141,551
20152,440
20162,976
20172,710
20183,587
20193,999
20203,696
20213,734
20223,599
20233,912
20244,566
20254,472
20262,826

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Qudexy XR (Topiramate)

2024 spending

$1.2M

Beneficiaries

106

653 claims

Per beneficiary

$11,206

$27.04 per unit

View as table
YearSpending
2020$3,423,118
2021$2,176,111
2022$1,641,617
2023$1,378,501
2024$1,187,783

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,003 on PubMed

Sponsor: Upsher Smith Labs

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.